Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review

Wilton, James; Senn, Heather; Sharma, Malika; Tan, Darrell H. S.
April 2015
HIV/AIDS - Research & Palliative Care;2015, Vol. 7, p125
Academic Journal
Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection. The use of daily tenofovir/ emtricitabine as oral PrEP was found to be effective in multiple placebo-controlled clinical trials and approved by the United States Food and Drug Administration. In addition, the Centers for Disease Control and Prevention in the United States and the World Health Organization have both released guidelines recommending the offer of oral PrEP to high-risk populations. The scale-up of PrEP is underway, but several implementation questions remain unanswered. Demonstration projects and open-label extensions of placebo-controlled trials are ongoing and hope to contribute to our understanding of PrEP use and delivery outside the randomized controlled trial setting. Evidence is beginning to emerge from these open-label studies and will be critical for guiding PrEP scale-up. Outside of such studies, PrEP uptake has been slow and several client- and provider-related barriers are limiting uptake. Maximizing the public health impact of PrEP will require rollout to be combined with interventions to promote uptake, support adherence, and prevent increases in risk behavior. Additional PrEP strategies are currently under investigation in placebo-controlled clinical trials and may be available in the future.


Related Articles

  • Pre-exposure prophylaxis for HIV prevention under review by Food and Drug Administration.  // Contraceptive Technology Update;Jul2012 STI Quarterly, p1 

    The article reports on a 2012 decision which the U.S. Food and Drug Administration made to approve the drug Truvada, in conjunction with condoms and other safe sex measures, for the prevention of HIV in individuals at risk of acquiring the virus through sexual activity.

  • Update: Use of HIV drugs shrinks infection risk in uninfected people.  // Contraceptive Technology Update;Mar2011 Supplement 2, p1 

    Use of powerful antiretroviral drugs, known as preexposure prophylaxis (PrEP), is being weighed as an addition to the HIV prevention arsenal with the positive results from a new clinical trial. • Researchers found that among men who have sex with men who took a single daily tablet...

  • HIV prevention pill prescription.  // New Scientist;5/24/2014, Vol. 222 Issue 2970, p7 

    The article discusses a pre-exposure prophylactic drug called Truvada for the prevention of HIV and updated clinical guidelines for its use in May 2014 by the U.S. Centers for Disease Control and Prevention (CDC).

  • Observatory. Infectious Disease.  // MLO: Medical Laboratory Observer;Nov2015, Vol. 47 Issue 11, p6 

    The article reports that the U.S. Centers for Disease Control and Prevention supports the new World Health Organization (WHO) directive to expand anti-retroviral treatment for all Human immunodefficiency virus (HIV) positive individuals regardless of CD-4 cell count.

  • Combined HIV prevention strategies work best for gay or straight couples.  // HIV Treatment ALERTS!;Nov2014, p3 

    The article presents a mathematical analysis at the Centers for Disease Control and Prevention (CDC). The study suggests that combining HIV prevention strategies, using antiretroviral therapy and the use of condoms, can offer the best long-term protection against HIV transmission in gay couples...

  • Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings. Havers, Fiona P.; Detrick, Barbara; Cardoso, Sandra W.; Berendes, Sima; Lama, Javier R.; Sugandhavesa, Patcharaphan; Mwelase, Noluthando H.; Campbell, Thomas B.; Gupta, Amita // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Study Background: Vitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between antiretrovirals used to treat HIV and reduced serum vitamin D...

  • When to start ART in Africa -- primarily guided by RCTs or patient autonomy? Delva, Wim; Fleming, Yvette; Chingandu, Lois // Journal of the International AIDS Society;2013, Vol. 16 Issue 1, p1 

    The authors discuss the need for antiretroviral tharapy (ART) to prevent the spread of HIV infections in Africa. They are critical of the article by Centers for Disease Control and Prevention (CDC) scientists that a randomized controlled trial (RCT) would be used to assess the benefits and...

  • 'This Is a Game Changer'. Hardy, Bill // Outlook Ohio Magazine;Jun2015, Vol. 20 Issue 1, p81 

    The article offers the author's insights on the use of pre-exposure prophylaxis (PrEP) in preventing HIV-negative individuals from contracting HIV. Topics include the effectiveness of PrEP, such as Truvada, in reducing the risk of HIV transmission, the support of the U.S. Centers for Disease...

  • Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection. Jereb, John A.; Goldberg, Stefan V.; Powell, Krista; Villarino, M. Elsa; LoBue, Philip // MMWR: Morbidity & Mortality Weekly Report;12/9/2011, Vol. 60 Issue 48, p1650 

    The article provides recommendations from the U.S. Centers for Disease Control and Prevention (CDC) for utilizing a isoniazid (INH)-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. The regimen can be regarded for other categories of patients when it provides practical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics